The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2014

Filed:

Apr. 09, 2010
Applicants:

John S. Mcmurray, Houston, TX (US);

Pijus K. Mandal, Houston, TX (US);

Warren S. Liao, Houston, TX (US);

Fredika Robertson, Houston, TX (US);

Xiaomin Chen, Houston, TX (US);

Ramesh Rajaopal, Sugarland, TX (US);

Zhiyong Ren, Houston, TX (US);

Inventors:

John S. McMurray, Houston, TX (US);

Pijus K. Mandal, Houston, TX (US);

Warren S. Liao, Houston, TX (US);

Fredika Robertson, Houston, TX (US);

Xiaomin Chen, Houston, TX (US);

Ramesh Rajaopal, Sugarland, TX (US);

Zhiyong Ren, Houston, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/05 (2006.01); A61P 35/00 (2006.01); C07K 1/00 (2006.01); C07F 9/40 (2006.01); C07F 9/553 (2006.01); C07F 9/572 (2006.01); C07F 9/12 (2006.01); A61K 31/66 (2006.01); C07F 9/6539 (2006.01); C07F 9/6561 (2006.01); A61K 31/437 (2006.01);
U.S. Cl.
CPC ...
C07F 9/5721 (2013.01); C07F 9/5532 (2013.01); C07F 9/12 (2013.01); A61K 31/66 (2013.01); C07F 9/6539 (2013.01); C07F 9/5728 (2013.01); C07F 9/6561 (2013.01); A61K 31/437 (2013.01);
Abstract

Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor.


Find Patent Forward Citations

Loading…